Group 1 - The company, Aomei Medical, announced a share buyback of approximately 1.99 million shares, representing 0.3138% of its total share capital, with a total expenditure of about 18 million yuan [1][1][1] - The highest transaction price during the buyback was 9.26 yuan per share, while the lowest was 8.33 yuan per share [1][1][1] - As of the report, Aomei Medical's market capitalization stands at 5.9 billion yuan [1][1][1] Group 2 - For the first half of 2025, Aomei Medical's revenue composition shows that medical devices accounted for 94.13%, while other segments contributed 5.87% [1][1][1]

Core Viewpoint - Aomei Medical (002950.SZ) has repurchased a total of 1,987,400 shares through the Shenzhen Stock Exchange, representing 0.3138% of the company's total share capital, with a total expenditure of 18,001,207.00 yuan [1] Summary by Category - **Share Repurchase Details** - The company repurchased 1,987,400 shares, accounting for 0.3138% of its total share capital [1] - The highest transaction price was 9.26 yuan per share, while the lowest was 8.33 yuan per share [1] - The total amount paid for the repurchase was 18,001,207.00 yuan, excluding stamp duty and transaction commissions [1]

截至 2025 年 9 月 30 日，公司累计通过深圳证券交易所交易系统以集中竞价交易方 式回购公司股份 1,987,400 股，占公司目前总股本的比例为 0.3138%，最高成交价为 9.26 元/股，最低成交价为 8.33 元/股，支付的总金额为 18,001,207.00 元（不含印花税、 交易佣金等交易费用）。 二、其他说明 截至目前，本次回购实施情况与回购股份方案不存在差异。公司后续将根据市场情况 在回购期限内实施本次回购计划，并按照相关法律法规的规定及时履行信息披露义务。敬 请广大投资者关注后续公告，并注意投资风险。 特此公告。 证券代码：002950 证券简称：奥美医疗 公告编号：2025-047 奥美医疗用品股份有限公司 关于股份回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开第 三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回购公司股份， 用 ...

证券代码：002950 证券简称：奥美医疗 公告编号：2025-046 奥美医疗用品股份有限公司 注：表中部分合计数与明细数直接相加之和在尾数上如有差异，系因四舍五入造成。 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）近日接到控股股东、实际 控制人之一崔金海先生的函告，获悉崔金海先生持有的本公司部分股份办理了 质押业务，具体事项如下： | 是否为控股 | 股东或第一 | 本次质押股 | 占其所持股 | 占公司总股 | 是否为限售 | 是否为补充 | 质押开始日 | 质押到期日 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 质权人 | 用途 | 大股东及其 | 数（股） | 份比例（%） | 本比例（%） | 股 | 质押 | 期 | 期 | | | | | | | 一致行动人 | | ...

Core Viewpoint - The company is facing challenges in maintaining its market value despite strong operational performance and growth, with significant concerns raised by investors regarding its stock price and market positioning compared to competitors [2][4]. Company Performance - As of September 22, 2025, the company's stock price closed at 9.47 yuan, down 0.73%, with a trading volume of 40,400 shares and a turnover of 38.26 million yuan [1]. - The company has been compared unfavorably to competitors, with its market capitalization significantly lower than that of peers like Zhend Medical and Sturdy Medical, which have market values approximately 2 to 5 times greater [4]. M&A Strategy - The company has indicated that its future merger and acquisition (M&A) focus will be on the health industry, emphasizing the importance of synergy and industry integration [2][3]. - The management has acknowledged the high risks associated with M&A activities and has adopted a cautious approach towards potential acquisitions [2]. Market Sentiment - Investor sentiment is currently negative, with concerns about the company's declining stock price despite its strong performance and generous dividend distribution over the years [2][4]. - On September 22, 2025, there was a net outflow of 1.19 million yuan from institutional investors, while retail investors contributed a net inflow of 6.11 million yuan [4].

Core Viewpoint - The company, Aomei Medical, has denied rumors regarding plans for asset restructuring involving the injection of AI chips and humanoid robots [1] Group 1 - An investor inquired about the authenticity of rumors related to Aomei Medical's potential asset restructuring [1] - Aomei Medical confirmed that there are no such plans in place [1]

Group 1 - The core point of the article is that Aomei Medical announced a share buyback program, having repurchased a total of 1,987,400 shares as of August 31, 2025, which represents 0.3138% of the company's total share capital [1]

Group 1 - The company approved a share repurchase plan on January 20, 2025, allowing for the repurchase of shares using its own funds and a special loan for share repurchase, with a maximum price of RMB 11.00 per share and a total repurchase amount between RMB 50 million and RMB 100 million [1] - The implementation period for the share repurchase is set for 12 months from the date of board approval [1] - The company will disclose the details of the repurchase plan through designated information disclosure media [1] Group 2 - As of August 31, 2025, the company has repurchased a total of 1,987,400 shares, accounting for 0.3138% of the total share capital, with a maximum transaction price of RMB 9.26 per share and a minimum of RMB 8.33 per share, totaling RMB 18,001,207.00 spent [2] - The implementation of the repurchase plan is consistent with the initial proposal, and the company will continue to execute the plan based on market conditions [3]

Core Viewpoint - Aomei Medical (002950.SZ) has announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Summary by Categories Share Buyback Details - The company has repurchased a total of 1.9874 million shares, which represents 0.3138% of its total share capital [1] - The highest transaction price during the buyback was 9.26 yuan per share, while the lowest was 8.33 yuan per share [1] - The total amount spent on the buyback was 18.0012 million yuan, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company, Aomei Medical (002950.SZ), announced a share buyback program, having repurchased a total of 1.9874 million shares as of August 31, 2025, which represents 0.3138% of its total share capital [1] - The highest transaction price during the buyback was 9.26 yuan per share, while the lowest was 8.33 yuan per share [1] - The total amount spent on the share buyback was 18.0012 million yuan, excluding stamp duty and transaction commissions [1]